Company Filing History:
2 out of 832,912 Years Active: 2002-2003
Title: The Innovations of Peter Lloyd Amlot
Introduction
Peter Lloyd Amlot is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of two patents to his name, Amlot's work focuses on innovative solutions for medical treatments.
Latest Patents
Amlot's latest patents include groundbreaking work on CD25 binding molecules. These monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they can be converted to chimeric or humanized forms, immunoconjugates, or antibody fragments. These products are particularly useful for the prophylaxis or treatment of transplant rejection, especially when combined with other antibodies to activated T-cells, such as CD7 antibodies. Another patent details methods of treatment using these CD25 binding molecules, emphasizing their potential in medical applications.
Career Highlights
Throughout his career, Amlot has focused on advancing the understanding and application of monoclonal antibodies. His innovative approaches have positioned him as a key figure in the biotechnology sector. His patents reflect a commitment to improving patient outcomes through targeted therapies.
Collaborations
Amlot has collaborated with esteemed colleagues, including Arne Nalpon Akbar and Günther Heinrich. These partnerships have fostered a collaborative environment